Nimotuzumab

DB06192InvestigationalProtein Based Therapies

Nimotuzumab is an EGFR-targeting monoclonal antibody used in the treatment of squamous cell carcinomas of the head and neck and glioblastomas. A cancer drug used to treat various forms of cancer, such as brain tumours and cancer of the head and neck.

Mechanism: Pharmacologically active on Epidermal growth factor receptor
Curator reviewed
Primary indication: Investigated for use/treatment in head and neck cancer, brain cancer, pediatric indications, pancreatic cancer, lung cancer, and colorectal cancer.Curator reviewed · 8 structured indications
Also known as: Nituzumab

Resolves to

Compound

UNII6NS400BXKHCAS780758-10-3

Targets

P00533EGFR

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

420Drug interactionsStructured to mechanism, not free text

135Clinical trialsPhase, status and sponsor resolved per trial

8Structured indicationsCondition, population, route and combination as fields, not prose

7ContraindicationsEach with its own population and attribute set

4Marketed productsAcross 3 countries and 3 labellers

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Nimotuzumab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account